Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Analytical Ultracentrifugation in Aotearoa: A Brief History of the Technique and its Place Among Other Tools Used to Investigate Biomolecular Interactions.

Journal of the Royal Society of New Zealand·2026

Same author

Targeting the MR1-MAIT Cell Axis for Vaccination Against Infectious Disease.

Vaccines·2026

Same author

Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens.

RSC medicinal chemistry·2026

Same author

Design and assessment of dimeric trehalose glycolipids as a strategy to enhance Mincle-mediated vaccine adjuvanticity.

Organic & biomolecular chemistry·2026

Same author

Natural Killer T follicular helper cell function permits germinal centre entry in nasal associated lymphoid tissue.

Mucosal immunology·2025

Same author

Highlights of 2024: Advances in Germinal Centers.

Immunology and cell biology·2025

Search research articles

Related Experiment Video

Updated: Aug 8, 2025

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

Harnessing NKT cells for vaccination.

Olivia K Burn¹, Theresa E Pankhurst², Gavin F Painter^3,4

¹Malaghan Institute of Medical Research, PO Box 7060, Wellington 6042, New Zealand.

Oxford Open Immunology

|February 27, 2023

Summary

Natural killer T (NKT) cell agonists show promise as immune adjuvants, enhancing vaccine responses by acting as universal helper cells. Targeted delivery may overcome limitations like hyporesponsiveness and toxicity, aiding infection prophylaxis and cancer therapy.

Keywords:

NKT adaptive immunity glycolipids innate-like T cells vaccine

More Related Videos

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: December 31, 2007

Related Experiment Videos

Last Updated: Aug 8, 2025

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Artificial Antigen Presenting Cell aAPC Mediated Activation and Expansion of Natural Killer T Cells

Published on: December 29, 2012

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System

Published on: October 4, 2024

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Interview: Glycolipid Antigen Presentation by CD1d and the Therapeutic Potential of NKT cell Activation

Published on: December 31, 2007

Area of Science:

Immunology
Vaccinology

Background:

Natural killer T (NKT) cells are innate-like T cells that enhance innate and adaptive immunity.
NKT cell agonists are explored as immune adjuvants due to their ability to induce strong antigen-specific responses when co-administered with antigens.
Activated NKT cells function as universal helper cells, providing signals to dendritic cells and B cells, potentially bypassing the need for conventional CD4+ T cell help.

Purpose of the Study:

To explore the potential of NKT cell agonists as immune adjuvants in vaccine development.
To address limitations associated with NKT cell activation, such as hyporesponsiveness and toxicity.
To highlight novel applications of NKT cell activation in promoting tissue-resident memory cells for infection prophylaxis and cancer therapy.

Main Methods:

Review of studies investigating NKT cell agonists as immune adjuvants.
Analysis of research on targeted delivery methods to overcome NKT cell activation drawbacks.
Examination of new findings on NKT cell-mediated differentiation of tissue-resident memory T cells.

Main Results:

NKT cell activation can induce strong immune responses, overriding conventional T cell help requirements.
Targeted delivery strategies show promise in mitigating NKT cell hyporesponsiveness and toxicity concerns.
NKT cell activation promotes the development of tissue-resident memory cells.

Conclusions:

NKT cell agonists represent a promising strategy for developing novel vaccines with broader applicability.
Overcoming limitations through targeted delivery is crucial for the clinical success of NKT cell-based immunotherapies.
NKT cell activation offers potential benefits for prophylaxis against infection and as a component of cancer therapy.